Resolution of inflammation during multiple sclerosis

Area of Science:

• Neuroimmunology
• Autoimmune diseases
• Inflammation biology

Background:

• Multiple sclerosis (MS) is a common autoimmune demyelinating disease of the central nervous system (CNS).
• MS presents in three forms: relapsing-remitting (RRMS), secondary progressive (SPMS), and primary progressive (PPMS), with inflammation present in all.
• Inflammation resolution mechanisms are critical but understudied in MS, particularly in the relapsing-remitting form.

Purpose of the Study:

• To review the active role of regulatory immune cells in inflammation resolution in MS.
• To discuss the contribution of tissue and non-hematopoietic cells to inflammation resolution.
• To explore the impact of disease-modifying therapies (DMTs), especially induction therapies, on inflammation resolution in MS.

Main Methods:

• Literature review focusing on neuroimmunology and inflammation resolution.
• Analysis of current understanding of immune cell roles in MS.
• Examination of DMT mechanisms related to inflammation resolution.

Main Results:

• Regulatory immune cells play an active role in resolving inflammation.
• Tissue and non-hematopoietic cells also contribute significantly to inflammation resolution.
• DMTs, particularly induction therapies, can leverage endogenous mechanisms to promote inflammation resolution in MS.

Conclusions:

• Understanding inflammation resolution is key to developing effective MS treatments.
• Targeting endogenous resolution pathways offers a promising therapeutic strategy for MS.
• Further research into immune and non-immune cell contributions to resolution is warranted for MS management.